British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.
After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.
John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.
Licencing bluebird bios Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market.
It is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as Amalgamator of Business and Biology.
Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.
QIAGEN and Illumina join forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration.